US · Healthcare · Biotechnology
EPS came in at -0.86 against a street estimate of -0.80 — a miss of 7.5%.
Analysts rate Biohaven Ltd. a buy (12 buy, 4 hold, 1 sell out of 17) with an average price target of $23.33.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.75% |
| Suvretta Capital Management, LLC | 6.81% |
| Stifel Financial Corp | 6.58% |
| Jupiter Topco LLC | 5.68% |
| Woodline Partners LP | 5.07% |
| State Street Corp | 4.60% |
| D. E. Shaw & Co LP | 2.77% |
| AQR Capital Management LLC | 2.75% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Biohaven reported a net loss of $129.279 million in Q3 2026 and $397.122 million for the first nine months, compared with $173.443 | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net loss was $129.3 million, or $0.86 per share, compared with $173.4 million, or $1.64 per share, in Q3 2025. • Non-GAAP | 2026-10-29 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • The FDA accepted Biohaven’s resubmitted new drug application (NDA) for Vyglxia (troriluzole) to treat spinocerebellar ataxia (SCA) | 2026-10-22 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • Biohaven entered a collaboration and license agreement with Ono Pharmaceutical Co., Ltd. on October 8, 2026. • Ono will pay Bioha | 2026-10-15 |
| Company announcement · Q3 2026 BIOHAVEN LTD. (BHVN) - FORM 8-K SUMMARY HEADLINE NUMBERS • Company received FDA partial clinical hold on September 4, 2026 on BHV-7000 program • Ove | 2026-09-10 |
| Material agreement · Q3 2026 BIOHAVEN LTD. - FORM 8-K SUMMARY (August 26, 2026) HEADLINE NUMBERS • Upfront payment from SK Biopharmaceuticals (SKBP): $400 million total ($350 mi | 2026-08-26 |
| Quarterly report · Q2 2026 BIOHAVEN LTD. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $238.0 million in cash and equivalents as of June 30, 2026 (down from $230.0 | 2026-08-10 |
| Results announced · Q3 2026 BIOHAVEN LTD. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net Loss Q2 2026: $137.3 million ($0.91 per share) vs. $198.1 million ($1.94 per share) | 2026-08-10 |
Readable in the app.
| Announcement | Date |
|---|---|
| Exclusive regional licensing deal with $80 million upfront payment and potential milestone Biohaven licensed rights to its MoDE pan-IgG degrader portfolio—led by BHV-1300 and including BHV-1310 and BHV-1320—to Ono Pharmaceutical for Japan, South Korea, Taiwan and ASEAN countries. | 2026-10-15 |
| Exclusive worldwide license agreement for Kv7 platform with $400M upfront Biohaven Bioscience signed a major licensing deal with SK Biopharmaceuticals (SKBP) on August 26, 2026, to license its Kv7 ion channel platform technology, including the experimental drug op | 2026-08-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biohaven Ltd. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.